Manufacturing

Clinigen acquires Japanese unlicensed medicines supplier

Clinigen Group has acquired International Medical Management (IMMC), Japan’s largest supplier of unlicensed medicines, for an undisclosed sum.

Amneal to acquire Impax to expand generics business in US

Amneal Pharmaceuticals has agreed to buy Impax Laboratories in an all-stock deal to create a diversified pharmaceutical firm that is expected to become the fifth largest generics business in the US.

Catalent to acquire Indiana-based CDMO Cook Pharmica for $950m

Catalent has agreed to acquire Indiana-based contract development and manufacturing organization (CDMO) Cook Pharmica for $950m to consolidate its position in the bio-pharma sector.

Bioverativ, Bicycle Therapeutics to develop therapies for hemophilia and sickle cell disease

Bioverativ and Bicycle Therapeutics have announced a research collaboration focused on the discovery, development and commercialization of innovative therapies for hemophilia and sickle cell disease.

Aptevo Therapeutics to sell hyperimmune commercial products

Aptevo Therapeutics has agreed to sell its three marketed hyperimmune products, WinRho SDF, HepaGam B, and VARIZIG, to Saol Therapeutics for total consideration of up to $74.5m.

AstraZeneca, Takeda to develop MEDI1341 for Parkinson’s disease

AstraZeneca and Takeda Pharmaceutical have entered into an agreement to jointly develop and commercialise MEDI1341, an alpha-synuclein antibody currently in development as a potential treatment for Parkinson’s disease (PD).

Celgene exercises option to extend strategic collaboration scope and term with Forma Therapeutics

Forma Therapeutics and Celgene announced an innovative R&D partnership in 2014 to pursue ground-breaking medicines in oncology and other therapeutic areas.

Gilead Sciences to buy Kite Pharma for $11.9bn

Biopharmaceutical firm Gilead Sciences has agreed to acquire US-based Kite Pharma for around $11.9bn.

Celgene, Sutro revise 2014 immuno-oncology collaboration

Celgene has revised the terms of its immuno-oncology collaboration with Sutro Biopharma, which was established in 2014.